Home | Volume 44 | Article number 184

Letter to the editors

Implementation of longitudinal insulin kinetic studies in busy field settings in Uganda: experience from the "glucose metabolism changes in Ugandan HIV patients on dolutegravir based anti-retroviral therapy" (GLUMED study)

Implementation of longitudinal insulin kinetic studies in busy field settings in Uganda: experience from the ‘glucose metabolism changes in Ugandan HIV patients on dolutegravir based anti-retroviral therapy´ (GLUMED study)

Frank Mulindwa1,2,&, Jean-Marc Schwarz3,4, Nele Brusselaers2,5,6, Simon Dujanga7, George Yendewa8, Barbara Castelnuovo1

 

1Makerere University Infectious Diseases Institute, Capacity Building Unit, Kampala, Uganda, 2Global Health Institute, Antwerp University, Antwerp, Belgium, 3University of California San Francisco, School of Medicine, California, United States of America, 4Department of Basic Sciences, Touro University California College of Osteopathic Medicine, Vallejo, California, United States of America, 5Centre for Translational Microbiome Research, Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, Stockholm, Sweden, 6Department of Head and Skin, Ghent University, Ghent, Belgium, 7Kampala City Council Authority Kisenyi Health Center IV HIV clinic, Kampala, Uganda, 8Department of Internal Medicine, Case Western Reserve University, Cleveland, Ohio, United States of America

 

 

&Corresponding author
Frank Mulindwa, Makerere University Infectious Diseases Institute, Capacity Building Unit, Kampala, Uganda

 

 

To the editors of the Pan African Medical Journal    Down

The Makerere University Infectious Diseases Institute (IDI) reported cases of patients presenting with accelerated hyperglycemia following switching to dolutegravir-anchored anti-retroviral therapy (ART) [1]. We sought to characterize glucose metabolism changes in Ugandan people living with HIV (PLHIV) by describing changes in insulin kinetics (insulin secretion, insulin resistance, and insulin clearance) in the first 48 weeks of dolutegravir (DTG)-based ART. One of the methods used to study insulin kinetics is the 75g oral glucose tolerance test (OGTT) with concurrent measurement of insulin and C-peptide in addition to the conventional 0, 30, 60, 90, and 120-minute blood glucose [2,3]. Most insulin kinetic studies have been performed in tailored laboratory and research institutional environments [4,5]. Performance of these studies in very busy field settings can be challenging due to the lack of space, sample processing equipment as well as sample storage facilities. We share our experience performing longitudinal insulin kinetic studies in a high-volume HIV clinic setting in Kampala-Uganda (Kisenyi Health Center IV HIV clinic) with over 12,000 active HIV patients in care.

The glucose metabolism changes in Ugandan HIV patients on dolutegravir (GLUMED) study was a prospective cohort study of 303 HIV-positive anti-retroviral therapy (ART) naive patients recruited between January and October 2021 and followed up for 48 weeks. Serial OGTTs were performed at 0,12 and 36 weeks.

The study nurse counselor called patients in advance to remind them of adhering to an overnight fast of 8-12 hours which was confirmed on arrival at the clinic. Venous access was established with 16-to-18-gauge venous cannulae. Portions of 75g of glucose were pre-packed into disposable cups on site and diluted in 300ml of water on study days, to be taken by the patient within 5 minutes after fasting blood samples were drawn. Serial 5ml blood samples were drawn at 30, 60, 90 and 120 minutes after the 75g glucose load with immediate measurement of blood glucose using ACCU-CHECK™ glucometers from Roche diagnostics. Blood samples were centrifuged in real time and serum samples stored temporarily in duplicate cryovials at -5 to -20°C in the HIV clinic laboratory freezer. At the end of the clinic day, frozen serum samples were transported in cooler boxes with ice packs to be stored at -80°C at the Makerere University Infectious Diseases Institute about fifteen minutes from the study clinic by a laboratory rider. Stored samples were to be used to run C-peptide and insulin assays at the end of the study.

We encountered various challenges in execution of the laboratory processes. There was lack of space to keep patients comfortable during the procedure as well as accommodate the laboratory equipment and personnel. To overcome this, a temporary tent had to be erected to house the study clinician, nurse and laboratory. Additionally, vascular access was hard to establish for some patients. There were occasional blockages of intravenous cannulae with consequent repeated cannulation which was an inconvenience to patients. On a few occasions, patients complained of dizziness and nausea after taking the glucose solution that the test had to be stopped. Despite the challenges, the acceptance rate for the laboratory procedures was high with only one patient dropping out of the study because they had become uncomfortable with the repeated blood draws.

Funding: the GLUMED study was funded by: National Institutes of Health (NIH)-Fogarty University of California (UCSF) global health fellowship program, grant number: 2D43TW009343-06; National Institutes of Health, UCSF-Gladstone Center for AIDS Research, grant number: P30AI027763; and the Fogarty International Centre, National Institute of Health (grant# 2D43TW009771-06 “HIV and co-infections in Uganda”).

 

 

Conclusion    Down

Performance of OGTT insulin kinetic studies is feasible even in busy routine ART clinic settings in limited resource settings so long as there is space, trained staff and facilities to ensure proper blood sample handling and storage.

 

 

Competing interests Up    Down

The authors declare no competing interest.

 

 

Authors´ contributions Up    Down

Frank Mulindwa, Jean-Marc Schwarz and Barbara Castelnuovo conceptualized the GLUMED study. Frank Mulindwa, Jean-Marc Schwarz, Nele Brusselaers, Simon Dujanga, George Yendewa and Barbara Castelnuovo participated in the implementation of the study. All the authors read and approved the final version of this manuscript.

 

 

Acknowledgements Up    Down

We thank the Kampala City Council Authority, Uganda, the Makerere University Infectious Diseases Institute, and the Kisenyi Health Center IV (HCIV) administration for authorizing the use of the study site. We also thank the Kisenyi HCIV HIV clinic staff for the support rendered to the GLUMED study and the patients for participating in the study.

 

 

References Up    Down

  1. Lamorde M, Atwiine M, Owarwo NC, Ddungu A, Laker EO, Mubiru F et al. Dolutegravir-associated hyperglycaemia in patients with HIV. Lancet HIV. 2020 Jul;7(7):e461-e462. PubMed | Google Scholar

  2. Tura A, Ludvik B, Nolan JJ, Pacini G, Thomaseth K. Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. Am J Physiol Endocrinol Metab. 2001 Nov;281(5):E966-74. PubMed | Google Scholar

  3. Seike M, Saitou T, Kouchi Y, Ohara T, Matsuhisa M, Sakaguchi K et al. Computational assessment of insulin secretion and insulin sensitivity from 2-h oral glucose tolerance tests for clinical use for type 2 diabetes. J Physiol Sci. 2011 Jul;61(4):321-30. PubMed | Google Scholar

  4. Schwarz JM, Noworolski SM, Erkin-Cakmak A, Korn NJ, Wen MJ, Tai VW et al. Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity. Gastroenterology. 2017 Sep;153(3):743-752. PubMed | Google Scholar

  5. Basu R, Dalla Man C, Campioni M, Basu A, Nair KS, Jensen MD et al. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care. 2007 Aug;30(8):1972-8. PubMed | Google Scholar